Home » Stocks » MRNA

Moderna, Inc. (MRNA)

Stock Price: $341.90 USD -7.42 (-2.12%)
Updated Jul 29, 2021 12:47 PM EDT - Market open
Market Cap 138.04B
Revenue (ttm) 2.73B
Net Income (ttm) 598.17M
Shares Out 400.00M
EPS (ttm) 1.49
PE Ratio 229.16
Forward PE 13.99
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $341.90
Previous Close $349.32
Change ($) -7.42
Change (%) -2.12%
Day's Open 351.00
Day's Range 336.00 - 351.22
Day's Volume 6,890,452
52-Week Range 54.21 - 362.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Moderna is riding high on the COVID-19 wave. Is it too late to get in?

6 hours ago - The Motley Fool

Analysts' lowest price targets for these widely held stocks implies some serious downside.

Other stocks mentioned: AMC, SHOP
6 hours ago - The Motley Fool

It could equal billions in revenue for the company.

6 hours ago - The Motley Fool

The biotech's sales and profits could exceed investors' expectations.

21 hours ago - The Motley Fool

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 6.2% at $348.47, rebounding after the stock dipped on Tuesday amid vaccine supply concerns. Vaccine stocks have also gained recently amid COVID-19 ...

21 hours ago - Benzinga

It's a big stretch.

1 day ago - The Motley Fool

The writing could already be on the wall.

Other stocks mentioned: PFE
1 day ago - The Motley Fool

Moderna (NASDAQ:MRNA) shares are trading lower on reports suggesting the company is having supply issues. According to a Reuters report, the company said that it does not have a sufficient stock of vacc...

1 day ago - Benzinga

FDA Requests Pfizer and Moderna to Expand Pediatric Trials

YouTube video

The Food and Drug Administration has requested Pfizer and Moderna to test their COVID vaccines in more children before seeking authorization to help rule out safety issues. The expanded pediatric trials...

Other stocks mentioned: PFE
1 day ago - Cheddar

The FDA requested a larger clinical trial for the company's vaccine in younger kids.

2 days ago - The Motley Fool

The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.

Other stocks mentioned: BNTX, PFE
2 days ago - CNET

The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.

Other stocks mentioned: BNTX, PFE
2 days ago - Forbes

Moderna confirmed to CNBC on Monday it plans to expand the size of its clinical trial testing its Covid-19 vaccine in kids ages 5 to 11.

2 days ago - CNBC

Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects,...

Other stocks mentioned: BNTX, PFE
2 days ago - Benzinga

Moderna entered the S&P 500 on July 21, 2021

YouTube video

#S&P500 #ModernaS&P500 Moderna replaced Alexion Pharmaceuticals Inc. in the S&P 500 effective prior to the opening of trading on Wed., July 21, according to a statement.

5 days ago - Yahoo Finance

Once again, their high efficacy could mean more market share.

Other stocks mentioned: BNTX, PFE
5 days ago - The Motley Fool

The biotech's sales and profits could soon receive another powerful boost.

5 days ago - The Motley Fool

Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.

Other stocks mentioned: AJRD, AZN, EBS, J, LDOS, LMT
5 days ago - Benzinga

When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock.

Other stocks mentioned: MORN, NTGR
5 days ago - Benzinga

The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales

Other stocks mentioned: BBH, FXH, IEIH, IYH
5 days ago - Zacks Investment Research

It was a jarring start to the week for Wall Street, with stocks in a seeming freefall as a rise in global Covid-19 cases, specifically the delta variant, had many wondering if the smooth economic recove...

Other stocks mentioned: AXP, IBM, JNJ, MCD, SNAP
5 days ago - Schaeffers Research

It comes after a study on more than 3,700 children.

6 days ago - CNET

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (Spikevax) f...

6 days ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--EMA CHMP adopts positive opinion recommending authorization for the use of the Moderna COVID-19 vaccine in adolescents (12-17 years of age) in the EU.

6 days ago - Business Wire

The most important detail investors want to know wasn't revealed.

6 days ago - The Motley Fool

Past performance isn't necessarily indicative of future success -- but in this case it might just be.

6 days ago - The Motley Fool

Concerns about the delta variant are rising.

Other stocks mentioned: BNTX, NVAX
6 days ago - The Motley Fool

Moderna, Pfizer, and Johnson & Johnson are optimistic.

Other stocks mentioned: JNJ, PFE
6 days ago - The Motley Fool

Moderna (MRNA) closed at $323.48 in the latest trading session, marking a +0.74% move from the prior day.

6 days ago - Zacks Investment Research

The company keeps scoring new supply deals across the Pacific.

6 days ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces establishment of new charitable foundation.

6 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Taiwan for 2022 and 2023.

1 week ago - Business Wire

Coronavirus variants will be the key variable.

Other stocks mentioned: BNTX, JNJ, PFE
1 week ago - The Motley Fool

Vaccination rates will determine what happens next.

1 week ago - The Motley Fool

There are four possible answers.

Other stocks mentioned: PFE
1 week ago - The Motley Fool

Fauci: Vaccines are safe and effective against delta variant

YouTube video

"We just need to get more and more people vaccinated," Dr. Anthony Fauci, chief medical advisor to President Biden, tells 'Closing Bell.' He emphasizes the need for data-based conclusions, like the fact...

Other stocks mentioned: BNTX, JNJ, PFE
1 week ago - CNBC Television

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study demonstrated that DehydraTECH enabled...

1 week ago - Benzinga

Dr. Vin Gupta explains why he's encouraging patients who received the single-shot J&J Covid vaccine to get a Pfizer or Moderna booster shot.

Other stocks mentioned: BNTX, JNJ, PFE
1 week ago - CNBC

Moderna's stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&P 500 on Wednesday.

1 week ago - Reuters

Momentum stocks turn the idea of "buy low, sell high" on its head. These seven stocks are on the rise and don't show signs of stopping.

Other stocks mentioned: CARR, DUK, EQR, OTIS, RVI, SLI
1 week ago - InvestorPlace

The vaccine sector is in the spotlight again today, with Moderna Inc (NASDAQ:MRNA) at the masthead.

1 week ago - Schaeffers Research

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...

Other stocks mentioned: IMNM, NRBO, NVAX, OCGN, QDEL
1 week ago - InvestorPlace

Moderna stock rallied by more than 20% over the last week, significantly outperforming the S&P 500 which was down by about 1%. The recent rally comes as Moderna is set to be included in the S&P 500 inde...

1 week ago - Forbes

Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight session. What Happened: Cambridge...

1 week ago - Benzinga

It isn't about to get any cheaper anytime soon.

1 week ago - The Motley Fool

Even if you love these stocks, it may not be a bad move to cash out right now.

Other stocks mentioned: FUBO, PINS
1 week ago - The Motley Fool

Moderna Inc (NASDAQ: MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) will purchase and distribute an additional 50 millio...

1 week ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of Moderna's COVID-19 Vaccine & booster vaccine candidate in 2022.

Other stocks mentioned: TAK
1 week ago - Business Wire

The investment thesis for these high-flying stocks no longer holds water.

Other stocks mentioned: AMC, GME
1 week ago - The Motley Fool

They could result in a broader market for Pfizer's vaccine.

Other stocks mentioned: PFE
1 week ago - The Motley Fool

About MRNA

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu... [Read more...]

Industry
Biotechnology
IPO Date
Dec 7, 2018
CEO
Stephane Bancel
Employees
1,300
Stock Exchange
NASDAQ
Ticker Symbol
MRNA
Full Company Profile

Financial Performance

In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 184.92, which is a decrease of -45.91% from the latest price.

Price Target
$184.92
(-45.91% downside)
Analyst Consensus: Buy